Comprehensive screening of genes resistant to an anticancer drug in esophageal squamous cell carcinoma

Tsutsui,Mai; Kawakubo,Hirofumi; Hayashida,Testsu; Fukuda,Kazumasa; Nakamura,Rieko; Takahashi,Tsunehiro; Wada,Norihito; Saikawa,Yoshiro; Omori,Tai; Takeuchi,Hiroya; Kitagawa,Yuko

doi:10.3892/ijo.2015.3085

Comprehensive screening of genes resistant to an anticancer drug in esophageal squamous cell carcinoma

Authors:
- Mai Tsutsui
- Hirofumi Kawakubo
- Testsu Hayashida
- Kazumasa Fukuda
- Rieko Nakamura
- Tsunehiro Takahashi
- Norihito Wada
- Yoshiro Saikawa
- Tai Omori
- Hiroya Takeuchi
- Yuko Kitagawa
View Affiliations

Affiliations: Department of Surgery, School of Medicine, Keio University, Shinjuku-ku, Tokyo 160-8582, Japan
Published online on: July 16, 2015 https://doi.org/10.3892/ijo.2015.3085
Pages: 867-874
Copyright: © Tsutsui et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Drug resistance to chemotherapy is a major issue in esophageal cancer management. Drug resistance may be mediated by genetic changes in the tumor; therefore, the identification of gene mutations may lead to better therapeutic outcomes. We used a novel method involving transposons to screen and identify drug-resistant genes. Transposons are DNA sequences that move from one location on the gene to another. A modified piggyBac transposon was designed as an insertion mutagen, and a cytomegalovirus (CMV) promoter sequence was added to induce strong transcription. When the transposon is inserted to the upstream of a certain gene, the gene will be overexpressed while when intserted down or intragenically, it will be downregulated. After establishing a transposon-tagged cell library, we treated cell lines derived from esophageal squamous cell carcinomas (ESCC) [Tohoku esophagus (TE)] with cisplatin (CDDP). We performed splinkerette PCR and TOPO cloning on the resistant colonies. Bacterial colonies were sequenced, and next-generation sequencing was used to identify the overexpressed/downregulated sequences as candidate genes for CDDP resistance. We established 4 cell lines of transposon-tagged cells, TE4, 5, 9 and 15. We treated the two relatively viable cell lines, TE4 and TE15, with CDDP. We identified 37 candidate genes from 8 resistant colonies. Eight genes were overexpressed whilst 29 were downregulated. Among these genes was Janus kinase 2 (JAK2) that is implicated in the progression of myeloproliferative neoplasms. We identified 37 candidate genes responsible for CDDP resistance in the two cell lines derived from ESCC cells. The method is inexpensive, relatively simple, and capable of introducing activating and de-activating mutations in the genome, allowing for drug-resistant genes to be identified.

View Figures

View References

1	Zacherl J: The current evidence in support of multimodal treatment of locally advanced, potentially resectable esophageal cancer. Dig Dis. 32:171–175. 2014. View Article : Google Scholar : PubMed/NCBI
2	Minsky BD, Pajak TF, Ginsberg RJ, Pisansky TM, Martenson J, Komaki R, Okawara G, Rosenthal SA and Kelsen DP: INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: High-dose versus standard-dose radiation therapy. J Clin Oncol. 20:1167–1174. 2002. View Article : Google Scholar : PubMed/NCBI
3	Ando N, Iizuka T, Ide H, Ishida K, Shinoda M, Nishimaki T, Takiyama W, Watanabe H, Isono K, Aoyama N, et al; Japan Clinical Oncology Group. Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: A Japan Clinical Oncology Group Study - JCOG9204. J Clin Oncol. 21:4592–4596. 2003. View Article : Google Scholar : PubMed/NCBI
4	Ando N, Kato H, Igaki H, Shinoda M, Ozawa S, Shimizu H, Nakamura T, Yabusaki H, Aoyama N, Kurita A, et al: A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol. 19:68–74. 2012. View Article : Google Scholar
5	Zhu L, Du H, Shi M, Chen Z and Hang J: ATG deficiency promote apoptotic death induced by Cisplatin in human esophageal squamous cell carcinoma cells. Bull Cancer. 100:15–21. 2013.PubMed/NCBI
6	Sato Y, Motoyama S, Nanjo H, Ito S, Yoshino K, Sasaki T, Kuribayashi K, Nagaki Y, Imai K, Saito H, et al: REG1A expression status suggests chemosensitivity among advanced thoracic esophageal squamous cell carcinoma patients treated with esophagectomy followed by adjuvant chemotherapy. Ann Surg Oncol. 20:3044–3051. 2013. View Article : Google Scholar : PubMed/NCBI
7	Guo W, Zhao YP, Jiang YG, Wang RW, Hong L and Fan DM: Upregulation of ZNRD1 enhances cisplatin resistance in human esophageal cancer cells by regulation of ERCC1 and Bcl-2. Tumour Biol. 29:188–194. 2008. View Article : Google Scholar : PubMed/NCBI
8	Hesketh PJ: Chemotherapy-induced nausea and vomiting. N Engl J Med. 5: 358:2482–2494. 2008. View Article : Google Scholar : PubMed/NCBI
9	Nooter K, Kok T, Bosman FT, van Wingerden KE and Stoter G: Expression of the multidrug resistance protein (MRP) in squamous cell carcinoma of the oesophagus and response to pre-operative chemotherapy. Eur J Cancer. 34:81–86. 1998. View Article : Google Scholar : PubMed/NCBI
10	Wen J, Zheng B, Hu Y, Zhang X, Yang H, Luo KJ, Zhang X, Li YF and Fu JH: Establishment and biological analysis of the EC109/CDDP multidrug-resistant esophageal squamous cell carcinoma cell line. Oncol Rep. 22:65–71. 2009.PubMed/NCBI
11	Sakai NS, Samia-Aly E, Barbera M and Fitzgerald RC: A review of the current understanding and clinical utility of miRNAs in esophageal cancer. Semin Cancer Biol. 23(6 Pt B): 512–521. 2013. View Article : Google Scholar : PubMed/NCBI
12	Kihara C, Tsunoda T, Tanaka T, Yamana H, Furukawa Y, Ono K, Kitahara O, Zembutsu H, Yanagawa R, Hirata K, et al: Prediction of sensitivity of esophageal tumors to adjuvant chemotherapy by cDNA microarray analysis of gene-expression profiles. Cancer Res. 61:6474–6479. 2001.PubMed/NCBI
13	Shimoji T, Miki Y and Nagasaki K: Gene expression profiling for prediction of response to chemotherapy. Gan To Kagaku Ryoho. 33:1–5. 2006.(In Japanese). PubMed/NCBI
14	Chen LI, Stuart L, Ohsumi TK, Burgess S, Varshney GK, Dastur A, Borowsky M, Benes C, Lacy-Hulbert A and Schmidt EV: Transposon activation mutagenesis as a screening tool for identifying resistance to cancer therapeutics. BMC Cancer. 13:932013. View Article : Google Scholar : PubMed/NCBI
15	Li X, Burnight ER, Cooney AL, Malani N, Brady T, Sander JD, Staber J, Wheelan SJ, Joung JK, McCray PB Jr, et al: PiggyBac transposase tools for genome engineering. Proc Natl Acad Sci USA. 110:E2279–E2287. 2013. View Article : Google Scholar : PubMed/NCBI
16	Hay RJ, Park J-G and Gazdar A: Atlas of Human Tumor Cell Lines. Academic Press; pp. 269–282. 1994
17	Nishihira T, Hashimoto Y, Katayama M, Mori S and Kuroki T: Molecular and cellular features of esophageal cancer cells. J Cancer Res Clin Oncol. 119:441–449. 1993. View Article : Google Scholar : PubMed/NCBI
18	Siddik ZH: Cisplatin: Mode of cytotoxic action and molecular basis of resistance. Oncogene. 22:7265–7279. 2003. View Article : Google Scholar : PubMed/NCBI
19	Ihle JN and Gilliland DG: Jak2: Normal function and role in hematopoietic disorders. Curr Opin Genet Dev. 17:8–14. 2007. View Article : Google Scholar : PubMed/NCBI
20	Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ, Boggon TJ, Wlodarska I, Clark JJ, Moore S, et al: Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 7:387–397. 2005. View Article : Google Scholar : PubMed/NCBI
21	Sumi K, Tago K, Kasahara T and Funakoshi-Tago M: Aurora kinase A critically contributes to the resistance to anti-cancer drug cisplatin in JAK2 V617F mutant-induced transformed cells. FEBS Lett. 585:1884–1890. 2011. View Article : Google Scholar : PubMed/NCBI
22	Wang LS, Chow KC and Wu CW: Expression and up-regulation of interleukin-6 in oesophageal carcinoma cells by n-sodium butyrate. Br J Cancer. 80:1617–1622. 1999. View Article : Google Scholar : PubMed/NCBI
23	Suchi K, Fujiwara H, Okamura S, Okamura H, Umehara S, Todo M, Furutani A, Yoneda M, Shiozaki A, Kubota T, et al: Overexpression of Interleukin-6 suppresses cisplatin-induced cytotoxicity in esophageal squamous cell carcinoma cells. Anticancer Res. 31:67–75. 2011.PubMed/NCBI